reports
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1...
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host co...
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral C...
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 Company will host conference call and live webcast to review and discuss the data at 8:00 am ET NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursda...
FreightCar America, Inc. to Attend Sidoti Virtual Conference
FreightCar America, Inc. to Attend Sidoti Virtual Conference CHICAGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced that Nick Randall, Chief Executive Officer, and Michael Riordan, Chief Financial Officer, will participate in one-on-one meetings with investors at Sidoti's Year End Virtual Investor Conference on December 11, 2025.For additional information or to request a meeting, please contact the Company’s In...
FreightCar America, Inc. to Present at NobleCon21
FreightCar America, Inc. to Present at NobleCon21 CHICAGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced that Nick Randall, Chief Executive Officer, and Michael Riordan, Chief Financial Officer, will present and participate in one-on-one meetings with investors at Noble Capital Markets’ Emerging Growth Equity Conference on December 3, 2025 in Boca Raton, Florida. For additional information or to request a meet...
- Wedbush Research
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
AXTI AXT INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
NICE NICE LTD
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
ORIC INC.
PLTR ORIC PHARMACEUTICALS
SNOW PALANTIR TECHNOLOGIES
XOS SNOWFLAKE INC. CLASS A
STX XOS INC.
TMC SEAGATE TECHNOLOGY HLDGS PLC
EMBRAC B THE METALS COMPANY INC
CRBP EMBRACER GROUP AB
LAC. CORBUS PHARMACEUTICALS HOLDINGS INC.
RNAC LITHIUM AMERICAS CORP NEW
STUB CARTESIAN THERAPEUTICS INC
STUBHUB HOLDINGS INC.
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results an...
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start mid-2026Completed $75 million public offering, extending cash runway into 2028Expected to complete CRB-913 SAD/MAD study and initiate Ph1b study in obese patients in Q4 2025 NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Comp...
FreightCar America, Inc. Reports Third Quarter 2025 Results
FreightCar America, Inc. Reports Third Quarter 2025 Results Delivered 42% revenue growth year-over-year Strong gross margins of 15.1%, expansion of 80 basis points Reaffirming Adjusted EBITDA guidance for full year CHICAGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today reported results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Revenues of $160.5 million, compared to $113.3 million...
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be participating in the following investor conferences. Guggenheim’s Second Annual Healthcare Innovation Conference in BostonFormat: Presentation and one-on-one investor meetings Date: November 12, 2025 Presentation time: 1:00pm ET Webcast link: Jefferies Global Healthcare Conference in LondonFormat: Presentation and one-on-one in...
Corbus Pharmaceuticals Announces Pricing of Public Offering
Corbus Pharmaceuticals Announces Pricing of Public Offering NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total public offering size of...
Corbus Pharmaceuticals Announces Proposed Public Offering
Corbus Pharmaceuticals Announces Proposed Public Offering NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance a...
FreightCar America, Inc. To Release Third Quarter 2025 Results On Nove...
FreightCar America, Inc. To Release Third Quarter 2025 Results On November 10, 2025 CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ: RAIL), a diversified manufacturer of railroad freight cars, today announced that it will release its third quarter 2025 financial results on Monday, November 10, 2025, before the market opens and host a teleconference to discuss its third quarter 2025 results on the same day. Teleconference details are as follows: November 10, 202511:00 a.m. Eastern TimePhone: 1-877-407-0789 or 1-201-689-8562Webcast access: Please note that the...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PRAX IDEAYA BIOSCIENCES
TVTX PRAXIS PRECISION MEDICINES
TLS TRAVERE THERAPEUTICS INC
DASH TELOS
ABNB DOORDASH
SNOW AIRBNB INC. CLASS A
STX SNOWFLAKE INC. CLASS A
VERA SEAGATE TECHNOLOGY HLDGS PLC
GFS VERA THERAPEUTICS INC
PL GLOBALFOUNDRIES INC
YOU PLANET LABS PBC
EWTX CLEAR SECURE INC
RUM EDGEWISE THERAPEUTICS INC
CRBP RUMBLE INC
CART CORBUS PHARMACEUTICALS HOLDINGS INC.
MAZE MAPLEBEAR INC.
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in H...
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in mid-2026Company to host an HNSCC KOL event during ESMO25 NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presente...
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 for its Phase 1/2 clinical study has been released. Updated data will be presented as a poster duri...
- Wedbush Research
RARE ULTRAGENYX PHARMACEUTICAL INC.
QLYS QUALYS INC.
PANW PALO ALTO NETWORKS INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
FTNT FORTINET INC.
CYBR CYBERARK SOFTWARE LTD.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
ARVN ARVINAS HOLDING
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
DDOG DATADOG INC CLASS A
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
TNGX TANGO THERAPEUTICS
TCRX INC
GLUE TSCAN THERAPEUTICS INC
S MONTE ROSA THERAPEUTICS INC
TYRA SENTINELONE INC
NUVL TYRA BIOSCIENCES INC
CRBP NUVALENT INC
RBRK CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX RUBRIK INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
ISR ISORAY
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TCRX TSCAN THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
NUVL NUVALENT INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX BICARA THERAPEUTICS INC.
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Wedbush Research
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
ACRS ACLARIS THERAPEUTICS INC.
FRX_CN FENNEC PHARMACEUTICALS
TMHC TAYLOR MORRISON HOME CORPORATION
WVE WAVE LIFE SCIENCES
MHO M/I HOMES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
IDYA IDEAYA BIOSCIENCES
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
STUB STUBHUB HOLDINGS INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.